APC Expands its US Presence with New Offices in Cambridge, MA

APC Ltd., the Applied Process Company, today announced the opening of new offices located at 245 Main St., Cambridge, MA. Responding to the growth in its client base in the Cambridge and the greater Boston area, APC is establishing a dedicated presence in the locale to better serve the needs of those clients requiring state of the art API process development services in both large and small molecules.  Initially Business Development, Marketing and Project Management services will operate from the new office space, with the potential for process development laboratory space being planned for the medium term. Further to this, and in support of developing the Boston market, APC is expanding its US sales team with the appointment of a new Business Development Director position to this area.

To celebrate this expansion, APC cordially invites interested parties to attend a Complimentary Knowledge Sharing Workshop, titled Particle Engineering, Crystallization and Process Scale-up, on 7^th of March where a series of thought leadership presentations, case studies and panel discussions will be delivered by a wide-range of subject-matter experts (SMEs) from both APC and external industry guest speakers. For more information and to register your attendance, visit: www.approcess.com/apc-workshop/

This announcement follows on from the completion of a €10M investment growing APC’s market leading R&D facilities in Dublin to 60,000 sq. ft., including the joint-investment of €2M with a client partner to successfully launch a biologics pilot plant facility, complete with fully-integrated process analytical technologies (PAT) and process modelling, capable of handling up to 500 L scale manufacturing processes.

Jennie Lynch, Vice President Life Sciences in Enterprise Ireland Boston, commented: “This expansion reflects APC’s continued growth within the US market, and is also evidence to the growing demand for their specialized process development services within the pharmaceutical and biotechnology industries.”

Mark Barrett, Chief Executive Officer & Co-Founder of APC commented: “APC continues to invest to meet the needs of our client partners. We recognize the proximity of APC services and personnel to our clients as being a key focus for our ongoing global growth. In tandem with significant capital investment at our Dublin headquarters, APC will continue to invest to provide first in class API process development services in both large and small molecules”.